Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121590 | 0.81 | ADORA3 (0.32) | — | |
| SCHEMBL20564 | 0.76 | ADORA3 (0.38) | KDM4EALDH1A1 | |
| SCHEMBL1146282 | 0.74 | PDE4B (0.34) | LMNA | |
| SCHEMBL4298076 | 0.73 | MEN1 (0.39) | — | |
| SCHEMBL15695429 | 0.73 | PIK3CA (0.30) | — | |
| SCHEMBL4239753 | 0.72 | PNP (0.34) | KDM4EALDH1A1LMNA | |
| SCHEMBL4360864 | 0.70 | MAPT (0.37) | KDM4EALDH1A1HPGDKDM4CLMNA | |
| SCHEMBL12639910 | 0.70 | MAPK13 (0.37) | KDM4EHPGDHTTKDM4C | |
| SCHEMBL12726686 | 0.69 | CSNK2A2 (0.33) | KDM4EALDH1A1LMNA | |
| SCHEMBL13522498 | 0.69 | ADORA1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048203-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | KDM4E 2911/4885ALDH1A1 355/4885HPGD 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.